Meridian Bioscience Inc. (NASDAQ:VIVO) EVP Richard Eberly sold 4,926 shares of the firm’s stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $17.00, for a total value of $83,742.00. Following the transaction, the executive vice president now owns 48,719 shares of the company’s stock, valued at approximately $828,223. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Shares of Meridian Bioscience Inc. (NASDAQ:VIVO) opened at 17.25 on Tuesday. The company’s 50 day moving average price is $17.49 and its 200-day moving average price is $18.91. Meridian Bioscience Inc. has a 52 week low of $15.75 and a 52 week high of $21.49. The company has a market capitalization of $725.98 million, a price-to-earnings ratio of 22.70 and a beta of 0.94.

Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, November 10th. The company reported $0.14 EPS for the quarter, meeting analysts’ consensus estimates of $0.14. Meridian Bioscience had a return on equity of 19.91% and a net margin of 16.44%. The business earned $47 million during the quarter, compared to analysts’ expectations of $47.17 million. During the same quarter in the prior year, the firm earned $0.20 earnings per share. The business’s revenue was down .2% compared to the same quarter last year. Analysts anticipate that Meridian Bioscience Inc. will post $0.82 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Monday, November 21st will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, November 17th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.64%. Meridian Bioscience’s payout ratio is currently 105.26%.

Several research firms have weighed in on VIVO. Hilliard Lyons cut Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Zacks Investment Research cut Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Wednesday, September 28th. Canaccord Genuity reiterated a “hold” rating and issued a $20.00 target price on shares of Meridian Bioscience in a report on Monday, August 1st. TheStreet cut Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, November 10th. Finally, Craig Hallum cut Meridian Bioscience from a “buy” rating to a “hold” rating and set a $19.00 target price for the company. in a report on Monday, November 14th. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $19.75.

Several institutional investors have recently made changes to their positions in the stock. Prudential Financial Inc. boosted its position in shares of Meridian Bioscience by 3.9% in the first quarter. Prudential Financial Inc. now owns 100,591 shares of the company’s stock worth $2,073,000 after buying an additional 3,800 shares during the last quarter. Mondrian Investment Partners LTD boosted its position in shares of Meridian Bioscience by 13.2% in the second quarter. Mondrian Investment Partners LTD now owns 149,891 shares of the company’s stock worth $2,923,000 after buying an additional 17,502 shares during the last quarter. Brown Capital Management LLC boosted its position in shares of Meridian Bioscience by 0.3% in the second quarter. Brown Capital Management LLC now owns 5,724,776 shares of the company’s stock worth $111,633,000 after buying an additional 14,900 shares during the last quarter. Nomura Holdings Inc. purchased a new position in shares of Meridian Bioscience during the second quarter worth approximately $226,000. Finally, Cardinal Capital Management raised its stake in Meridian Bioscience by 6.5% in the second quarter. Cardinal Capital Management now owns 34,218 shares of the company’s stock worth $667,000 after buying an additional 2,081 shares during the period. 85.29% of the stock is owned by institutional investors and hedge funds.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

5 Day Chart for NASDAQ:VIVO

Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.